Product Information
WIXELA 100-50 INHUB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.1188 per EA under NDC 00378932032. Its NADAC has been published 384 times since Apr 17, 2019.
FDA first approved this application on Jan 30, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100; 50 ug/1; ug/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378932032
Classification
Generic
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
Generic (ANDA)
FDA Application
ANDA208891FDA Approved
1/30/2019
TE Code
AB
On Market Since
2/11/2019
Pharmacological Classes
Price Statistics
The NADAC for WIXELA 100-50 INHUB has been published 384 times since Apr 17, 2019, and over the history we have for it it has declined 65.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1188 per EA |
|---|---|
| All-time high | $3.2445 (May 15, 2019) |
| All-time low | $0.8022 (May 22, 2024) |
| 52-week high | $1.2255 |
| 52-week low | $1.1188 |
| Median price | $1.4028 |
| Average price | $1.5817 |
| Largest weekly change | +53.1% (Jun 19, 2024) |
| Weeks tracked | 384 |
| Tracking since | Apr 17, 2019 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of WIXELA 100-50 INHUB?
The current National Average Drug Acquisition Cost (NADAC) for WIXELA 100-50 INHUB, manufactured by Mylan Pharmaceuticals Inc., is $1.1188 per EA (NDC 00378932032), effective Aug 19, 2026.
How has the price of WIXELA 100-50 INHUB changed over time?
Over the history we have for it, the NADAC for WIXELA 100-50 INHUB has declined 65.5%. It has been tracked across 384 weekly CMS publications since Apr 17, 2019.
What are the highest and lowest recorded NADAC prices for WIXELA 100-50 INHUB?
Since Apr 17, 2019, the NADAC for WIXELA 100-50 INHUB has ranged from a low of $0.8022 (May 22, 2024) to a high of $3.2445 (May 15, 2019), with a median of $1.4028 per EA.
Are there cheaper alternatives to WIXELA 100-50 INHUB?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as WIXELA 100-50 INHUB in a comparable dosage form, but none are currently priced below it.
Who manufactures WIXELA 100-50 INHUB?
WIXELA 100-50 INHUB (NDC 00378932032) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.